XERS Q2 2022 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M+184.1% YoY

Gross Profit

$20M81.0% margin

Operating Income

-$19M-74.7% margin

Net Income

-$26M-103.5% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+14.6%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$319M

Total Liabilities

$245M

Stockholders' Equity

$74M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$9M	+184.1%
Gross Profit	$20M	$6M	+271.1%
Operating Income	-$19M	-$26M	+26.6%
Net Income	-$26M	-$28M	+4.8%

Revenue Segments

Product

$25M66%

Keveyis

$13M34%